UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

A randomised study comparing the effectiveness of acupuncture or morphine versus the combination for the relief of dyspnoea in patients with advanced non-small cell lung cancer and mesothelioma

European journal of cancer (1990), 2016-07, Vol.61, p.102-110

2016

Volltextzugriff (PDF)

Mechanism and non-mechanism based imaging biomarkers for assessing biological response to treatment in non-small cell lung cancer

European journal of cancer (1990), 2016-05, Vol.59, p.65-78

2016

Volltextzugriff (PDF)

Adjuvant Erlotinib (E) Versus Placebo (P) for Completely Resected Stage IB-IIIA EGFR-Positive (IHC/FISH) Non-Small Cell Lung Cancer (NSCLC): RADIANT Results

International journal of radiation oncology, biology, physics, 2014-11, Vol.90 (5), p.S2-S3

2014

Volltextzugriff (PDF)

Patient factors, health care factors and survival from lung cancer according to ethnic group in the south of London, UK

European journal of cancer care, 2013-01, Vol.22 (1), p.79-87

2013

Volltextzugriff (PDF)

1207 POSTER Phase I Dose-Finding Study for Pazopanib (P) and Paclitaxel (T) in Combination in the First-line Setting in Patients (pts) With Advanced Solid Tumours

European journal of cancer (1990), 2011, Vol.47, p.S146-S146

2011

Volltextzugriff (PDF)

1500TiP REFINE-Lung is a multicentre phase III study to determine the optimal frequency of pembrolizumab in non-small cell lung cancer utilising a novel multi-arm design

Annals of oncology, 2023-10, Vol.34, p.S845-S845

2023

Volltextzugriff (PDF)

2207P Mainstream germline genetic testing in routine oncological care of EGFR mutant non-small cell lung cancer in the United Kingdom

Annals of oncology, 2023-10, Vol.34, p.S1140-S1140

2023

Volltextzugriff (PDF)

Chronic obstructive pulmonary disease in lung cancer – underdiagnosed and undertreated

Lung cancer (Amsterdam, Netherlands), 2009, Vol.63, p.S24-S24

2009

Volltextzugriff (PDF)

Phase II trial of ZD0473 as second-line therapy in mesothelioma

European journal of cancer (1990), 2002-12, Vol.38, p.S19-S24

2002

Volltextzugriff (PDF)

AKT inhibition synergistically enhances growth-inhibitory effects of gefitinib and increases apoptosis in non-small cell lung cancer cell lines

Lung cancer (Amsterdam, Netherlands), 2014-08, Vol.85 (2), p.141-146

2014

Volltextzugriff (PDF)

An audit of neutropaenia in patients with small cell lung carcinoma (SCLC) undergoing platinum-based chemotherapy – urgent need for specific SCLC guidelines

Lung cancer (Amsterdam, Netherlands), 2009, Vol.63, p.S13-S13

2009

Volltextzugriff (PDF)

Audit of epidermal growth factor receptor (EGFR) expression by immunohistochemistry (IHC) using Dako and Ventana clones in non-small cell lung cancer (NSCLC)

Lung cancer (Amsterdam, Netherlands), 2009, Vol.63, p.S2-S3

2009

Volltextzugriff (PDF)

The value of day 8 blood count in treatment decisions when using oral vinorelbine in non-small cell lung cancer (NSCLC) patients

Lung cancer (Amsterdam, Netherlands), 2009, Vol.63, p.S4-S4

2009

Volltextzugriff (PDF)

Mesothelioma and radical surgery trial (MARS): the feasibility study process

Lung cancer (Amsterdam, Netherlands), 2009, Vol.63, p.S26-S26

2009

Volltextzugriff (PDF)

180P Incidence of brain metastases (BM) in newly diagnosed stage IV NSCLC during COVID-19

Journal of thoracic oncology, 2021-04, Vol.16 (4), p.S795-S795

2021

Volltextzugriff (PDF)

163P Circulating tumour (ct) DNA next generation sequencing (NGS) in UK advanced non-small cell lung cancer (aNSCLC) patients (pts)

Journal of thoracic oncology, 2021-04, Vol.16 (4), p.S787-S788

2021

Volltextzugriff (PDF)

1541P Real-world data of atezolizumab plus carboplatin-etoposide for patients with extensive stage SCLC: The UK experience

Annals of oncology, 2022-09, Vol.33, p.S1251

2022

Volltextzugriff (PDF)

930MO PD-L1 expression and outcomes of pembrolizumab and placebo in completely resected stage IB-IIIA NSCLC: Subgroup analysis of PEARLS/KEYNOTE-091

Annals of oncology, 2022-09, Vol.33, p.S971-S972

2022

Volltextzugriff (PDF)

The Predictive Value of the G8 Questionnaire in Older Patients with Lung Cancer or Mesothelioma before Systemic Treatment

Clinical oncology (Royal College of Radiologists (Great Britain)), 2023-02, Vol.35 (2), p.e163-e172

2023

Volltextzugriff (PDF)

VP3-2022: Pembrolizumab (pembro) versus placebo for early-stage non-small cell lung cancer (NSCLC) following complete resection and adjuvant chemotherapy (chemo) when indicated: Randomized, triple-blind, phase III EORTC-1416-LCG/ETOP 8-15 – PEARLS/KEYNOTE-091 study

Annals of oncology, 2022-04, Vol.33 (4), p.451-453

2022

Volltextzugriff (PDF)

Under usage of zoledronic acid in non-small cell lung cancer patients with metastatic bone disease – a short communication

European journal of cancer (1990), 2011-07, Vol.47 (11), p.1603-1605

2011

Volltextzugriff (PDF)

Time and Chemotherapy Treatment Trends in the Treatment of Elderly Patients (Age ≥ 70 Years) with Non-small Cell Lung Cancer

Clinical oncology (Royal College of Radiologists (Great Britain)), 2008-03, Vol.20 (2), p.142-147

2008

Volltextzugriff (PDF)

40P Lorlatinib-associated weight gain and dyslipidaemia: A single centre UK experience

ESMO open, 2024-03, Vol.9, p.102619, Article 102619

2024

Volltextzugriff (PDF)

193O Long-term outcomes after concurrent once- or twice-daily chemoradiation in limited-stage small cell lung cancer: A brief report from the CONVERT trial

ESMO open, 2024-03, Vol.9, p.102766, Article 102766

2024

Volltextzugriff (PDF)

Diagnostic EGFR testing with ctDNA versus tumour in patients with advanced non-small cell lung cancer (NSCLC): The Royal Marsden experience

Annals of oncology, 2017-04, Vol.28, p.ii34-ii35

2017

Volltextzugriff (PDF)

1 – 25 von 89

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(88)
Mit Volltextzugriff
(89)

Publikationsform

Artikel
(88)
Reviews
(1)

Sprache

Englisch
(89)
Japanisch
(3)

Erscheinungsjahr

n.n

Thema

Humans
(34)
Life Sciences & Biomedicine
(32)
Science & Technology
(32)
Female
(28)
Middle Aged
(27)
Oncology
(27)
Aged
(26)
Adult
(21)
Male
(21)
Biological And Medical Sciences
(20)
Medical Sciences
(20)
Hematology, Oncology And Palliative Medicine
(18)
Chemotherapy
(14)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(12)
Pharmacology. Drug Treatments
(12)
Lung Neoplasms - Drug Therapy
(11)
Treatment Outcome
(10)
Aged, 80 And Over
(9)
Antineoplastic Agents
(9)
Pulmonary/respiratory
(9)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Annals Of Oncology
(28)
Lung Cancer
(16)
European Journal Of Cancer
(15)
Clinical Oncology
(5)
Immuno-Oncology Technology
(4)
Breast
(3)
The Lancet
(3)
Esmo Open
(2)
European Journal Of Cancer Care
(2)
European Journal Of Cancer Supplements
(2)

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

A randomised study comparing the effectiveness of acupuncture or morphine versus the combination for the relief of dyspnoea in patients with advanced non-small cell lung cancer and mesothelioma

Mechanism and non-mechanism based imaging biomarkers for assessing biological response to treatment in non-small cell lung cancer

Adjuvant Erlotinib (E) Versus Placebo (P) for Completely Resected Stage IB-IIIA EGFR-Positive (IHC/FISH) Non-Small Cell Lung Cancer (NSCLC): RADIANT Results

Patient factors, health care factors and survival from lung cancer according to ethnic group in the south of London, UK

1207 POSTER Phase I Dose-Finding Study for Pazopanib (P) and Paclitaxel (T) in Combination in the First-line Setting in Patients (pts) With Advanced Solid Tumours

1500TiP REFINE-Lung is a multicentre phase III study to determine the optimal frequency of pembrolizumab in non-small cell lung cancer utilising a novel multi-arm design

2207P Mainstream germline genetic testing in routine oncological care of EGFR mutant non-small cell lung cancer in the United Kingdom

Chronic obstructive pulmonary disease in lung cancer – underdiagnosed and undertreated

Phase II trial of ZD0473 as second-line therapy in mesothelioma

AKT inhibition synergistically enhances growth-inhibitory effects of gefitinib and increases apoptosis in non-small cell lung cancer cell lines

An audit of neutropaenia in patients with small cell lung carcinoma (SCLC) undergoing platinum-based chemotherapy – urgent need for specific SCLC guidelines

Audit of epidermal growth factor receptor (EGFR) expression by immunohistochemistry (IHC) using Dako and Ventana clones in non-small cell lung cancer (NSCLC)

The value of day 8 blood count in treatment decisions when using oral vinorelbine in non-small cell lung cancer (NSCLC) patients

Mesothelioma and radical surgery trial (MARS): the feasibility study process

180P Incidence of brain metastases (BM) in newly diagnosed stage IV NSCLC during COVID-19

163P Circulating tumour (ct) DNA next generation sequencing (NGS) in UK advanced non-small cell lung cancer (aNSCLC) patients (pts)

1541P Real-world data of atezolizumab plus carboplatin-etoposide for patients with extensive stage SCLC: The UK experience

930MO PD-L1 expression and outcomes of pembrolizumab and placebo in completely resected stage IB-IIIA NSCLC: Subgroup analysis of PEARLS/KEYNOTE-091

The Predictive Value of the G8 Questionnaire in Older Patients with Lung Cancer or Mesothelioma before Systemic Treatment

VP3-2022: Pembrolizumab (pembro) versus placebo for early-stage non-small cell lung cancer (NSCLC) following complete resection and adjuvant chemotherapy (chemo) when indicated: Randomized, triple-blind, phase III EORTC-1416-LCG/ETOP 8-15 – PEARLS/KEYNOTE-091 study

Under usage of zoledronic acid in non-small cell lung cancer patients with metastatic bone disease – a short communication

Time and Chemotherapy Treatment Trends in the Treatment of Elderly Patients (Age ≥ 70 Years) with Non-small Cell Lung Cancer

40P Lorlatinib-associated weight gain and dyslipidaemia: A single centre UK experience

193O Long-term outcomes after concurrent once- or twice-daily chemoradiation in limited-stage small cell lung cancer: A brief report from the CONVERT trial

Diagnostic EGFR testing with ctDNA versus tumour in patients with advanced non-small cell lung cancer (NSCLC): The Royal Marsden experience

Suchergebnisse filtern